Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Disability rights activist and author Alice Wong dies at 51 - 2Winona Ryder didn't take the 'Stranger Things' plot lightly. How 'otherworldly' grief and a kidnapping in her hometown informed her character.
- 3If everyone on Earth sat in the ocean at once, how much would sea level rise?
- 4Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 5Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- Which One Energizes You the Most These Tech Developments
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- How does spider venom damage human cells? Researchers uncover the killer mechanism of recluse spider toxin
- Very good quality Greens All over The Planet
- Iran-backed Iraqi militias attack Kurdistan over 450 times since beginning of war
- Rediscovering Experience Through Excursions: Individual Travel Stories
- Lily Allen 2026 'West End Girl' arena tour: How to get tickets, prices and more
- The Most Compelling Innovation Advancements Somewhat recently
- Consumer experts: German petrol hikes rule won't bring down prices
